Viatris Inc. (VTRS) is a global healthcare company valued at a market cap of $12 billion. It focuses on providing affordable medicines across a wide range of therapeutic areas, including ...

Viatris (VTRS) is set to report Q3 results on Thursday, November 6, before the market opens. Analysts expect EPS of $0.62, ...

Viatris Inc. closed 22.29% short of its 52-week high of $13.55, which the company achieved on November 25th.

Viatris Inc. closed 22.80% below its 52-week high of $13.55, which the company reached on November 25th.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

Investing.com - Viatris (NASDAQ: VTRS) reported third quarter EPS of $0.67, $0.05 better than the analyst estimate of $0.62. Revenue for the quarter came in at $3.76B versus the consensus estimate of ...

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible ...

The latest announcement is out from Viatris ( (VTRS) ).

Viatris (VTRS) delivered earnings and revenue surprises of +6.35% and +3.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?